Evidence map›Paper›PMID 33348583›Full record

ReviewViruses2020

The Unknown Unknowns: Recovering Gamma-Delta T Cells for Control of Human Immunodeficiency Virus (HIV).

Shivkumar Biradar, Michael T Lotze, Robbie B Mailliard

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shivkumar BiradarDepartment of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Michael T LotzeDepartments of Surgery, Immunology, and Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Robbie B MailliardDepartment of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-5501-503X
University of Pittsburgh · US

Funding

University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
University of Pittsburgh MWCCS Clinical Research SiteU01HL146208 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Bernard Jonas C Macatangay, CHARLES R RINALDO · 2019 to 2026
$32.2M
Targeting HMGB1-mediated Autophagy in Cancer TherapyR01CA160417 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2012 to 2023
$3.0M
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognitionR01CA206012 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FACCIABENE, ANDREA · 2016 to 2020
$2.0M
Mechanisms of Ferroptotic Cancer Cell DeathR01CA229275 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2019 to 2024
$1.8M
Targeting PYK2 for the treatment of PDACR01CA236965 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HU, JING · 2020 to 2024
$1.8M
Immunometabolism in SepsisR01GM115366 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI BILLIAR, TIMOTHY R, TANG, DAOLIN · 2015 to 2018
$1.2M
Programming Dendritic Cells to Expose the Persistent HIV-1 Latent Reservoir for Immune TargetingR21AI131763 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MAILLIARD, ROBBIE B · 2017 to 2018
$429k
Replication Competent HIV-1 in Blood and TissuesR21AI138716 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MAILLIARD, ROBBIE B · 2018 to 2019
$426k
NCI NIH HHS R01 CA160417NCI NIH HHS R01 CA206012NCI NIH HHS R01 CA229275NCI NIH HHS R01 CA236965NHLBI NIH HHS U01 HL146208NIAID NIH HHS R21 AI131763NIAID NIH HHS R21 AI138716NIGMS NIH HHS R01 GM115366
6 · The paper itself

Abstract

Recent advances in γδ T cell biology have focused on the unique attributes of these cells and their role in regulating innate and adaptive immunity, promoting tissue homeostasis, and providing resistance to various disorders. Numerous bacterial and viral pathogens, including human immunodeficiency virus-1 (HIV), greatly alter the composition of γδ T cells in vivo. Despite the effectiveness of antiretroviral therapy (ART) in controlling HIV and restoring health in those affected, γδ T cells are dramatically impacted during HIV infection and fail to reconstitute to normal levels in HIV-infected individuals during ART for reasons that are not clearly understood. Importantly, their role in controlling HIV infection, and the implications of their failure to rebound during ART are also largely unknown and understudied. Here, we review important aspects of human γδ T cell biology, the effector and immunomodulatory properties of these cells, their prevalence and function in HIV, and their immunotherapeutic potential.

Indexed as

Antigens, ViralBiomarkersHIV-1HIV InfectionsHLA AntigensHost-Pathogen InteractionsHumansIntraepithelial LymphocytesLigandsPhosphoproteinsT-Lymphocyte SubsetsAntigens, ViralBiomarkersHLA AntigensLigandsPhosphoproteinsgamma delta T cellHIVimmunotherapyVδ1Vδ2

Identifiers

PMID33348583
PMCPMC7766279
OpenAlexW3112165537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.